ValuEngine Downgrades Orthopediatrics (NASDAQ:KIDS) to Hold

Orthopediatrics (NASDAQ:KIDS) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday, ValuEngine reports.

A number of other equities analysts also recently commented on KIDS. BidaskClub upgraded Orthopediatrics from a “sell” rating to a “hold” rating in a report on Wednesday, July 17th. BTIG Research restated a “buy” rating and issued a $44.00 price objective on shares of Orthopediatrics in a report on Friday, May 10th. Needham & Company LLC started coverage on Orthopediatrics in a report on Wednesday, June 19th. They issued a “buy” rating and a $53.00 price objective on the stock. Finally, Zacks Investment Research downgraded Orthopediatrics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 14th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $46.75.

NASDAQ KIDS traded down $1.66 during trading hours on Thursday, hitting $34.76. 55,541 shares of the company’s stock were exchanged, compared to its average volume of 98,233. The stock has a 50 day simple moving average of $37.42. Orthopediatrics has a 12-month low of $25.11 and a 12-month high of $47.82. The firm has a market capitalization of $534.57 million, a price-to-earnings ratio of -36.21 and a beta of 0.12. The company has a quick ratio of 6.01, a current ratio of 8.60 and a debt-to-equity ratio of 0.26.

Orthopediatrics (NASDAQ:KIDS) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). The firm had revenue of $14.66 million during the quarter, compared to analysts’ expectations of $14.67 million. Orthopediatrics had a negative return on equity of 16.43% and a negative net margin of 16.71%. On average, research analysts anticipate that Orthopediatrics will post -0.45 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the business. Metropolitan Life Insurance Co. NY acquired a new stake in Orthopediatrics during the 4th quarter valued at approximately $93,000. American Century Companies Inc. acquired a new stake in Orthopediatrics during the 4th quarter valued at approximately $3,880,000. Bank of New York Mellon Corp grew its stake in Orthopediatrics by 14.3% during the 4th quarter. Bank of New York Mellon Corp now owns 21,500 shares of the company’s stock valued at $750,000 after purchasing an additional 2,697 shares in the last quarter. BlackRock Inc. grew its stake in Orthopediatrics by 12.4% during the 4th quarter. BlackRock Inc. now owns 455,657 shares of the company’s stock valued at $15,894,000 after purchasing an additional 50,179 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Orthopediatrics by 51.9% during the 4th quarter. Geode Capital Management LLC now owns 80,310 shares of the company’s stock valued at $2,801,000 after purchasing an additional 27,429 shares in the last quarter. Hedge funds and other institutional investors own 48.56% of the company’s stock.

About Orthopediatrics

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.

Featured Article: Why do company’s buyback their stock?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.